Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Table 1

Previous cases of nivolumab-induced Vogt–Koyanagi–Harada disease-like uveitis.

Authors	Year of publication	Age	Sex	Primary disease	ICI	Timing	Pleocytosis	HLA class II examination
Current case		72	M	Gastric cancer	Nivolumab	17 weeks	+ (142/μL)	HLA-DR4
Hwang et al. [8]	2022	61	F	Ovarian cancer	Nivolumab	12–16 weeks	NR	NR
Minami et al. [9]	2021	73	M	Metastatic melanoma	Nivolumab; Ipilimumab	25 days	NR	HLA-DR4
Ushio et al. [10]	2021	58	M	Non-small-cell lung cancer	Nivolumab	4 months	+ (16/μL)	HLA-DR4
Godse et al. [11]	2021	57	F	Metastatic melanoma	Nivolumab; Ipilimumab	3 months	NR	NR
Ng et al. [12]	2021	49	F	Metastatic renal cell carcinoma	Nivolumab; Ipilimumab	2 years	NR	NR
Czichos et al. [13]	2021	70	M	Metastatic renal cell carcinoma	Nivolumab		NR	None
Mihailovic et al. [14]	2020	68	F	Metastatic melanoma	Nivolumab; Ipilimumab		NR	NR
Gambichler et al. [15]	2020	63	F	Metastatic melanoma	Nivolumab		NR	NR
Kikuchi et al. [16]	2020	69	M	Hypopharyngeal cancer	Nivolumab	2 months	—	HLA-DRB104:05; HLA-DRB109:01
Obata et al. [17]	2019	63	F	Metastatic melanoma	Nivolumab	1 month and 10 days	NR	HLA-DR9
Fujimura et al. [18]	2018	73	M	Metastatic melanoma	Nivolumab; Dabrafenib; Trametinib		NR	HLA-DRB104:05
Fujimura et al. [18]	2017	35	F	Metastatic melanoma	Nivolumab; Dabrafenib; Trametinib		NR	HLA-DRB104:05
Arai et al. [19]	2017	55	M	Metastatic melanoma	Nivolumab	2 weeks	NR	HLA-DRB104:10; HLA-DRB104:06
Matsuo et al. [20]	2017	60	F	Metastatic melanoma	Nivolumab; Vemurafenib	6 weeks	NR	NR

NR: not reported; F: Female; M: Male; ICI: immune checkpoint inhibitors; HLA: human leukocyte antigen.